114 related articles for article (PubMed ID: 35691754)
21. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
22. A Randomized Controlled Trial Comparing Clinical Outcomes and Toxicity of Lobaplatin- Versus Cisplatin-Based Concurrent Chemotherapy Plus Radiotherapy and High-Dose-Rate Brachytherapy for FIGO Stage II and III Cervical Cancer.
Wang JQ; Wang T; Shi F; Yang YY; Su J; Chai YL; Liu Z
Asian Pac J Cancer Prev; 2015; 16(14):5957-61. PubMed ID: 26320479
[TBL] [Abstract][Full Text] [Related]
23. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
[TBL] [Abstract][Full Text] [Related]
24. Equivalent survival in patients with advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following chemoradiotherapy.
Carcopino X; Houvenaeghel G; Buttarelli M; Esterni B; Tallet A; Goncalves A; Jacquemier J
Eur J Surg Oncol; 2008 May; 34(5):569-75. PubMed ID: 17531428
[TBL] [Abstract][Full Text] [Related]
25. Split-field helical tomotherapy with or without chemotherapy for definitive treatment of cervical cancer.
Chang AJ; Richardson S; Grigsby PW; Schwarz JK
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):263-9. PubMed ID: 21167656
[TBL] [Abstract][Full Text] [Related]
26. Surgical versus clinical staging prior to primary chemoradiation in patients with cervical cancer FIGO stages IIB-IVA: oncologic results of a prospective randomized international multicenter (Uterus-11) intergroup study.
Marnitz S; Tsunoda AT; Martus P; Vieira M; Affonso Junior RJ; Nunes J; Budach V; Hertel H; Mustea A; Sehouli J; Scharf JP; Ulrich U; Ebert A; Piwonski I; Kohler C
Int J Gynecol Cancer; 2020 Dec; 30(12):1855-1861. PubMed ID: 33293284
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer.
Cima S; Perrone AM; Castellucci P; Macchia G; Buwenge M; Cammelli S; Cilla S; Ferioli M; Ferrandina G; Galuppi A; Salizzoni E; Rubino D; Fanti S; De Iaco P; Morganti AG
Int J Gynecol Cancer; 2018 Mar; 28(3):575-580. PubMed ID: 29372911
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of definitive chemoradiation followed by intracavitary pulsed-dose rate image-guided adaptive brachytherapy in locally advanced cervical cancer.
Castelnau-Marchand P; Chargari C; Maroun P; Dumas I; Del Campo ER; Cao K; Petit C; Martinetti F; Tafo-Guemnie A; Lefkopoulos D; Morice P; Haie-Meder C; Mazeron R
Gynecol Oncol; 2015 Nov; 139(2):288-94. PubMed ID: 26364808
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer.
Pötter R; Georg P; Dimopoulos JC; Grimm M; Berger D; Nesvacil N; Georg D; Schmid MP; Reinthaller A; Sturdza A; Kirisits C
Radiother Oncol; 2011 Jul; 100(1):116-23. PubMed ID: 21821305
[TBL] [Abstract][Full Text] [Related]
30. Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging - An analysis from the EMBRACE study.
Knoth J; Pötter R; Jürgenliemk-Schulz IM; Haie-Meder C; Fokdal L; Sturdza A; Hoskin P; Mahantshetty U; Segedin B; Bruheim K; Wiebe E; Rai B; Cooper R; van der Steen-Banasik E; van Limbergen E; Pieters BR; Sundset M; Tan LT; Nout RA; Tanderup K; Kirisits C; Nesvacil N; Lindegaard JC; Schmid MP
Gynecol Oncol; 2020 Oct; 159(1):136-141. PubMed ID: 32798000
[TBL] [Abstract][Full Text] [Related]
31. MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach.
Laliscia C; Gadducci A; Mattioni R; Orlandi F; Giusti S; Barcellini A; Gabelloni M; Morganti R; Neri E; Paiar F
Tumori; 2022 Aug; 108(4):376-385. PubMed ID: 34235995
[TBL] [Abstract][Full Text] [Related]
32. The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario.
Tiwari R; Narayanan GS; Jayakumar V; Narayanan S; Vishwanathan B; Mandal SK; Babu S; Ramya V; George D
Gynecol Oncol; 2018 Sep; 150(3):420-425. PubMed ID: 30017538
[TBL] [Abstract][Full Text] [Related]
33. Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study.
Sturdza AE; Pötter R; Kossmeier M; Kirchheiner K; Mahantshetty U; Haie-Meder C; Lindegaard JC; Jurgenliemk-Schulz I; Tan LT; Hoskin P; van Limbergen E; Gillham C; Segedin B; Tharavichitkul E; Iturre EV; Fokdal LU; Polterauer S; Kirisits C; Tanderup K
Int J Radiat Oncol Biol Phys; 2021 Sep; 111(1):168-177. PubMed ID: 33932530
[TBL] [Abstract][Full Text] [Related]
34. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
Hu K; Wang W; Liu X; Meng Q; Zhang F
Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the survival outcome of neoadjuvant therapy followed by radical surgery with that of concomitant chemoradiotherapy in patients with stage IB2-IIIB cervical adenocarcinoma.
Tian T; Gao X; Ju Y; Ding X; Ai Y
Arch Gynecol Obstet; 2021 Mar; 303(3):793-801. PubMed ID: 33009996
[TBL] [Abstract][Full Text] [Related]
36. Treatment Outcome and Prognosis Factors of FIGO 2018 Stage III Cervical Cancer Patients Treated with Definitive Concurrent Chemoradiation in Vietnam.
Phung HT; Truong MC; Nguyen LT; Dang ATV; Vu TH; Nguyen HT
Asian Pac J Cancer Prev; 2021 Mar; 22(3):853-859. PubMed ID: 33773550
[TBL] [Abstract][Full Text] [Related]
37. Predictors of distant relapse in patients with FIGO stage IIB-IVA cervical cancer treated with definitive radiotherapy.
Okazawa-Sakai M; Mabuchi S; Isohashi F; Kawashima A; Yokoi E; Ogawa K; Kimura T
J Obstet Gynaecol Res; 2017 Nov; 43(11):1743-1750. PubMed ID: 28816403
[TBL] [Abstract][Full Text] [Related]
38. Textural features of cervical cancers on FDG-PET/CT associate with survival and local relapse in patients treated with definitive chemoradiotherapy.
Chen SW; Shen WC; Hsieh TC; Liang JA; Hung YC; Yeh LS; Chang WC; Lin WC; Yen KY; Kao CH
Sci Rep; 2018 Aug; 8(1):11859. PubMed ID: 30089896
[TBL] [Abstract][Full Text] [Related]
39. Concurrent chemoradiation for cervical cancer: Comparison of LDR and HDR brachytherapy.
Lin AJ; Samson P; Zoberi J; Garcia-Ramirez J; Williamson JF; Markovina S; Schwarz J; Grigsby PW
Brachytherapy; 2019; 18(3):353-360. PubMed ID: 30971370
[TBL] [Abstract][Full Text] [Related]
40. Chemobrachyradiotherapy and consolidation chemotherapy in treatment of locally advanced cervical cancer : A retrospective single institution study.
Tomić K; Berić Jozić G; Parić A; Marijanović I; Lasić I; Soldo D; Vrdoljak E
Wien Klin Wochenschr; 2021 Nov; 133(21-22):1155-1161. PubMed ID: 34674038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
